China
· Delayed Price · Currency is CNY Jiangsu Hengrui Medicine Statistics
Total Valuation
Jiangsu Hengrui Medicine has a market cap or net worth of CNY 319.14 billion. The enterprise value is 296.88 billion.
| Market Cap | 319.14B |
| Enterprise Value | 296.88B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
Jiangsu Hengrui Medicine has 6.36 billion shares outstanding. The number of shares has decreased by -0.70% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 6.36B |
| Shares Change (YoY) | -0.70% |
| Shares Change (QoQ) | +1.34% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 20.21% |
| Float | 3.41B |
Valuation Ratios
The trailing PE ratio is 58.37 and the forward PE ratio is 53.96. Jiangsu Hengrui Medicine's PEG ratio is 4.49.
| PE Ratio | 58.37 |
| Forward PE | 53.96 |
| PS Ratio | 12.23 |
| PB Ratio | 7.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 50.80 |
| P/OCF Ratio | n/a |
| PEG Ratio | 4.49 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 47.60, with an EV/FCF ratio of 47.26.
| EV / Earnings | 54.49 |
| EV / Sales | 11.42 |
| EV / EBITDA | 47.60 |
| EV / EBIT | 54.39 |
| EV / FCF | 47.26 |
Financial Position
The company has a current ratio of 9.00, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.00 |
| Quick Ratio | 7.79 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,220.04 |
Financial Efficiency
Return on equity (ROE) is 12.88% and return on invested capital (ROIC) is 8.05%.
| Return on Equity (ROE) | 12.88% |
| Return on Assets (ROA) | 7.48% |
| Return on Capital (ROIC) | 8.05% |
| Revenue Per Employee | 1.33M |
| Profits Per Employee | 277,815 |
| Employee Count | 19,611 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.13% in the last 52 weeks. The beta is 0.29, so Jiangsu Hengrui Medicine's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -0.13% |
| 50-Day Moving Average | 48.02 |
| 200-Day Moving Average | 44.08 |
| Relative Strength Index (RSI) | 57.49 |
| Average Volume (20 Days) | 53,951,485 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jiangsu Hengrui Medicine had revenue of CNY 26.00 billion and earned 5.45 billion in profits. Earnings per share was 0.86.
| Revenue | 26.00B |
| Gross Profit | 22.26B |
| Operating Income | 5.46B |
| Pretax Income | 5.94B |
| Net Income | 5.45B |
| EBITDA | 6.20B |
| EBIT | 5.46B |
| Earnings Per Share (EPS) | 0.86 |
Balance Sheet
The company has 22.91 billion in cash and 87.58 million in debt, giving a net cash position of 22.82 billion or 3.59 per share.
| Cash & Cash Equivalents | 22.91B |
| Total Debt | 87.58M |
| Net Cash | 22.82B |
| Net Cash Per Share | 3.59 |
| Equity (Book Value) | 44.33B |
| Book Value Per Share | 6.98 |
| Working Capital | 30.63B |
Cash Flow
In the last 12 months, operating cash flow was 7.92 billion and capital expenditures -1.64 billion, giving a free cash flow of 6.28 billion.
| Operating Cash Flow | 7.92B |
| Capital Expenditures | -1.64B |
| Free Cash Flow | 6.28B |
| FCF Per Share | 0.99 |
Margins
Gross margin is 85.62%, with operating and profit margins of 21.00% and 20.96%.
| Gross Margin | 85.62% |
| Operating Margin | 21.00% |
| Pretax Margin | 22.86% |
| Profit Margin | 20.96% |
| EBITDA Margin | 23.85% |
| EBIT Margin | 21.00% |
| FCF Margin | 24.17% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.40%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.40% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.40% |
| Buyback Yield | 0.70% |
| Shareholder Yield | 1.09% |
| Earnings Yield | 1.71% |
| FCF Yield | 1.97% |
Stock Splits
The last stock split was on June 10, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 10, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
Jiangsu Hengrui Medicine has an Altman Z-Score of 44.27.
| Altman Z-Score | 44.27 |
| Piotroski F-Score | n/a |